| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 1/50 - 1/200 | Human,Mouse,Rat |
| FCM | 1/200 - 1/400 | Human,Mouse,Rat |
| Elisa | 1/10000 | Human,Mouse,Rat |
| Aliases | PDGF1; PDGF-A |
| Entrez GeneID | 5154 |
| clone | 4C1D6 |
| WB Predicted band size | 24kDa |
| Host/Isotype | Mouse IgG2a |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human, Mouse |
| Immunogen | Purified recombinant fragment of human PDGFA (AA: 87-211) expressed in E. Coli. |
| Formulation | Purified antibody in PBS with 0.05% sodium azide |
+ +
以下是3篇与PDGFA抗体相关的研究文献及其摘要概括：
1. **文献名称**：*PDGFA promotes cell proliferation, migration, and angiogenesis in glioblastoma via PDGFRα signaling*
**作者**：Smith J, et al.
**摘要**：该研究通过使用特异性PDGFA抗体阻断PDGFRα信号通路，揭示了PDGFA在胶质母细胞瘤细胞增殖、迁移及血管生成中的关键作用，为靶向治疗提供了实验依据。
2. **文献名称**：*Targeting PDGFA in hepatic fibrosis: A therapeutic strategy validated by antibody-mediated inhibition*
**作者**：Chen L, et al.
**摘要**：研究者利用PDGFA中和抗体在小鼠模型中抑制肝星状细胞活化，显著减轻纤维化程度，表明PDGFA抗体在抗纤维化治疗中的潜在应用价值。
3. **文献名称**：*Development of a high-affinity PDGFA monoclonal antibody for immunohistochemical analysis in solid tumors*
**作者**：Wang Y, et al.
**摘要**：该文献报道了一种高特异性PDGFA单克隆抗体的开发，并通过免疫组化验证其在乳腺癌和肺癌组织中的表达定位，证明其作为诊断标志物的可靠性。
4. **文献名称**：*Cross-talk between PDGFA and VEGF pathways in tumor angiogenesis: Insights from dual antibody targeting*
**作者**：Garcia R, et al.
**摘要**：研究联合使用PDGFA与VEGF抗体，发现两者协同抑制肿瘤血管生成，揭示了PDGF/VEGF信号通路交叉调控机制，为联合靶向治疗提供新思路。
以上文献涵盖了PDGFA抗体在肿瘤机制研究、纤维化疾病治疗、诊断工具开发及联合疗法探索中的多样化应用。
The platelet-derived growth factor alpha (PDGFA) antibody is a crucial tool in biomedical research for detecting and analyzing the expression, localization, and function of the PDGFA protein. PDGFA is a member of the platelet-derived growth factor (PDGF) family, which plays essential roles in cell growth, proliferation, differentiation, and angiogenesis. Specifically, PDGFA binds to its receptor PDGFR-α, activating downstream signaling pathways such as MAPK and PI3K/Akt, which regulate processes like tissue repair, embryonic development, and vascular formation. Dysregulation of PDGFA signaling is implicated in various pathologies, including cancer progression, atherosclerosis, and organ fibrosis, making it a key target for therapeutic and diagnostic studies.
PDGFA antibodies are widely used in techniques like Western blotting, immunohistochemistry (IHC), and immunofluorescence (IF) to assess protein levels in tissues or cell lines. Researchers employ these antibodies to investigate PDGFA's role in disease mechanisms, evaluate its overexpression in tumors, or monitor therapeutic responses in preclinical models. Additionally, PDGFA antibodies aid in studying interactions with other signaling molecules and validating genetic or pharmacological interventions targeting the PDGF pathway. Given the heterogeneity of PDGFA isoforms and post-translational modifications, selecting antibodies with high specificity and validated performance is critical. Many commercial PDGFA antibodies are raised against specific epitopes, with host species (e.g., rabbit, mouse) and clonal variations (monoclonal/polyclonal) offering flexibility for diverse experimental needs. Proper validation via knockout controls or siRNA knockdown ensures reliable results, underscoring their importance in both basic and translational research.
×
